Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.
The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.
Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials that could have skewed results as a reason for voting against the use of MDMA in PTSD patients, according to NPR.
Read Also: What's Going On With MindMed And Psychedelic Stocks?
美國食品與藥品管理局（FDA）的顧問小組於週二拒絕了MDMA作爲治療創傷後應激障礙（PTSD）的藥物，並指出缺乏證據表明將這種迷幻治療方法引入患者的風險超過了其益處。由於此項裁決，大多數太空概念的股票在週三都受到了打擊。
小組投票9-2認爲，當MDMA與心理治療結合使用時，並不能有效地對治療PTSD起到作用。該小組還以10-1的比例投票認爲，目前的益處並不能超過使用這種藥物治療精神問題的潛在風險。
根據NPR的報道，小組中的一些成員（如社會學家Elizabeth Joniak-Grant）認爲，由於試驗中的不當行爲指控可能導致結果出現偏差，因此拒絕在PTSD患者中使用MDMA。
讀者也應該看看：MindMed和迷幻股票發生了什麼？
Market Movers: Many stocks in the psychedelic space traded lower Wednesday following the ruling. Cybin Inc (NYSEAMERICAN:CYBN), which develops drugs and treatments derived from psychedelic substances like psilocybin, was down by more than 10% Wednesday afternoon.
Mind Medicine (NASDAQ:MNMD), another biotech using psychedelic substances as a derivative for its treatments, traded lower by more than 8% Wednesday. ATAI Life Sciences (NASDAQ:ATAI) opened Wednesday's trading session down more than 14% from its closing price Tuesday, but was able to recover some of its losses throughout Wednesday's session, and last traded down around 6%.
The AdvisorShares Psychedelics ETF (NYSE:PSIL), a fund that tracks many publicly traded psych stocks, traded around 6% lower Wednesday afternoon.
許多太空概念股票在週三的裁決後交易低迷。Cybin公司（NYSEAMERICAN:CYBN）研發基於類似於蘑菇的迷幻物質的藥物和治療方法，週三下午下跌超過10%。
Mind Medicine（NASDAQ:MNMD）是另一家將迷幻物質用作其治療方案的生物技術公司，週三下跌超過8%。ATAI Life Sciences（NASDAQ:ATAI）週三開盤股價比周二收盤價下跌了超過14%，但在週三的交易中恢復了一些損失，最後交易下跌約6%。
AdvisorShares Psychedelics ETF（NYSE:PSIL）是一隻追蹤許多公開交易的迷幻股票的基金，週三下午交易下跌約6%。
What's Next: While the FDA does not have to follow that advisory board's recommendation, the ruling was seen throughout the industry as a blow to the progress made in approving and regulating treatments that utilize psychedelics. Proponents of psych drugs argue that many show more effectiveness than mental health treatments currently available on the market.
儘管FDA不必遵循諮詢委員會的建議，但是此項裁決在整個行業中被視爲打擊了批准和監管使用迷幻物質治療的進展。精神藥物的支持者認爲，許多精神健康治療方法目前市場上的效果都沒有這些藥物好。
Now Read: Nvidia Has 'Multi-Year Lead' On AMD, Intel: Bank Of America Analyst Expects Stock To Hit $1,500 Per Share
現在閱讀：銀行分析師預計，英偉達股票價格將達到1,500美元，英特爾和AMD相比具有多年的領先優勢。
Photo: Shutterstock
Photo: shutterstock